c-Met 表达与多形性胶质母细胞瘤患者的复发时间有关。

c-Met expression is associated with time to recurrence in patients with glioblastoma multiforme.

机构信息

Department of Neurosurgery, Provincial Hospital affiliated to Shandong University, 324 Jingwuweiqi Road, Jinan, Shandong 250021, China.

出版信息

J Clin Neurosci. 2011 Jan;18(1):119-21. doi: 10.1016/j.jocn.2010.05.010. Epub 2010 Sep 15.

DOI:10.1016/j.jocn.2010.05.010

PMID:20832323

Abstract

The aim of this study was to explore the difference in c-Met expression between primary and recurrent glioblastoma multiforme (GBM), and to determine whether the dysregulation of c-Met expression has a role in the malignant progression of GBM. Paired primary and recurrent GBM specimens from the same patient were evaluated using immunohistochemical analysis. The association between c-Met expression and progression-free survival time (PFST) was analyzed. There was a significant difference in c-Met expression between primary and recurrent tumors (p=0.020), and patients with tumors expressing c-Met at a higher level had a significantly shorter PFST (6.1 months vs. 11.5 months; p=0.026). Our study indicates that recurrent GBM express c-Met at a higher level and that c-Met overexpression is associated with shorter PFST in patients with GBM. These findings suggest that c-Met potentially has an important role in the treatment of GBM.

摘要

本研究旨在探讨 c-Met 表达在原发性和复发性胶质母细胞瘤（GBM）之间的差异，并确定 c-Met 表达失调是否在 GBM 的恶性进展中发挥作用。使用免疫组织化学分析评估来自同一患者的配对原发性和复发性 GBM 标本。分析 c-Met 表达与无进展生存期（PFST）之间的关联。原发性和复发性肿瘤之间的 c-Met 表达存在显著差异（p=0.020），并且 c-Met 表达水平较高的患者的 PFST 明显更短（6.1 个月与 11.5 个月；p=0.026）。我们的研究表明，复发性 GBM 以更高水平表达 c-Met，并且 c-Met 过表达与 GBM 患者的 PFST 缩短相关。这些发现表明 c-Met 可能在 GBM 的治疗中具有重要作用。